152 related articles for article (PubMed ID: 27778323)
1. The incidence and mortality rates of neuroblastoma cases before and after the cessation of the mass screening program in Japan: A descriptive study.
Shinagawa T; Kitamura T; Katanoda K; Matsuda T; Ito Y; Sobue T
Int J Cancer; 2017 Feb; 140(3):618-625. PubMed ID: 27778323
[TBL] [Abstract][Full Text] [Related]
2. Effects of the Cessation of Mass Screening for Neuroblastoma at 6 Months of Age: A Population-Based Study in Osaka, Japan.
Ioka A; Inoue M; Yoneda A; Nakamura T; Hara J; Hashii Y; Sakata N; Yamato K; Tsukuma H; Kawa K
J Epidemiol; 2016; 26(4):179-84. PubMed ID: 26548355
[TBL] [Abstract][Full Text] [Related]
3. Secular trends in neuroblastoma mortality before and after the cessation of national mass screening in Japan.
Katanoda K; Hayashi K; Yamamoto K; Sobue T
J Epidemiol; 2009; 19(5):266-70. PubMed ID: 19652443
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of screening for neuroblastoma at 6 months of age: a retrospective population-based cohort study.
Hiyama E; Iehara T; Sugimoto T; Fukuzawa M; Hayashi Y; Sasaki F; Sugiyama M; Kondo S; Yoneda A; Yamaoka H; Tajiri T; Akazawa K; Ohtaki M
Lancet; 2008 Apr; 371(9619):1173-80. PubMed ID: 18395578
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of nationwide screening program for neuroblastoma in Japan.
Hisashige A;
Glob J Health Sci; 2014 Apr; 6(4):94-106. PubMed ID: 25001552
[TBL] [Abstract][Full Text] [Related]
6. Neuroblastoma Screening at 1 Year of Age: The Final Results of a Controlled Trial.
Berthold F; Spix C; Erttmann R; Hero B; Michaelis J; Treuner J; Ernst A; Schilling FH
JNCI Cancer Spectr; 2021 Jul; 5(4):. PubMed ID: 34240006
[TBL] [Abstract][Full Text] [Related]
7. Effects of mass screening for neuroblastoma on incidence, mortality, and survival rates in Osaka, Japan.
Ajiki W; Tsukuma H; Oshima A; Kawa K
Cancer Causes Control; 1998 Dec; 9(6):631-6. PubMed ID: 10189049
[TBL] [Abstract][Full Text] [Related]
8. Neuroblastoma trends in Osaka, Japan, and Great Britain 1970-1994, in relation to screening.
Honjo S; Doran HE; Stiller CA; Ajiki W; Tsukuma H; Oshima A; Coleman MP
Int J Cancer; 2003 Feb; 103(4):538-43. PubMed ID: 12478672
[TBL] [Abstract][Full Text] [Related]
9. Analysis of 598 cases of neuroblastoma (NB) detected by screening and changes in the age distribution and incidence of NB patients after mass screening in infants in Japan. NB Screening Study Group.
Sawada T; Shikata T; Matsumura T; Kawakatsu H; Sugimoto T
Prog Clin Biol Res; 1994; 385():371-5. PubMed ID: 7972233
[No Abstract] [Full Text] [Related]
10. Contribution of HPLC mass screening for neuroblastoma to a decrease in mortality.
Nishi M; Takeda T; Hatae Y; Hanai J; Fujita K; Ichimiya H; Tanaka T
J Exp Clin Cancer Res; 2002 Mar; 21(1):73-8. PubMed ID: 12071533
[TBL] [Abstract][Full Text] [Related]
11. [Present status of neuroblastoma mass screening in Japan. Neuroblastoma-Committee of the Japanese Childhood Cancer Society].
Sawada T; Nagahara N; Ohi R; Yamamoto K; Okabe I; Hanawa Y; Hashizume K; Matsui I; Ohkawa H; Tunoda A
Gan To Kagaku Ryoho; 1990 Dec; 17(12):2319-26. PubMed ID: 2260868
[TBL] [Abstract][Full Text] [Related]
12. Mass screening for neuroblastoma and mortality in birth cohorts.
Nishi M; Miyake H; Takeda T; Hanai J; Kikuchi Y; Takasugi N
Int J Cancer; 1997 May; 71(4):552-5. PubMed ID: 9178807
[TBL] [Abstract][Full Text] [Related]
13. Effects of mass screening on age-specific incidence of neuroblastoma.
Bessho F
Int J Cancer; 1996 Aug; 67(4):520-2. PubMed ID: 8759611
[TBL] [Abstract][Full Text] [Related]
14. Marginal decrease in mortality and marked increase in incidence as a result of neuroblastoma screening at 6 months of age: cohort study in seven prefectures in Japan.
Yamamoto K; Ohta S; Ito E; Hayashi Y; Asami T; Mabuchi O; Higashigawa M; Tanimura M
J Clin Oncol; 2002 Mar; 20(5):1209-14. PubMed ID: 11870162
[TBL] [Abstract][Full Text] [Related]
15. Past and future of neuroblastoma screening in Japan.
Sawada T
Am J Pediatr Hematol Oncol; 1992 Nov; 14(4):320-6. PubMed ID: 1456397
[TBL] [Abstract][Full Text] [Related]
16. Screening for neuroblastoma: a review of the evidence.
Chamberlain J
J Med Screen; 1994 Jul; 1(3):169-75. PubMed ID: 8790511
[TBL] [Abstract][Full Text] [Related]
17. Mass screening for neuroblastoma in Japan. Committee of the Neuroblastoma Mass Screening Study of the Japanese Society of Pediatric Oncology.
Sawada T; Nagahara N; Yamamoto K; Okabe I; Hanawa Y; Hashizume K; Matsui I; Okawa H; Tsunoda A; Sakurai M
Acta Paediatr Jpn; 1990 Dec; 32(6):725-33. PubMed ID: 2082676
[TBL] [Abstract][Full Text] [Related]
18. Neuroblastoma screening in Japan: population-based cohort study and future aspects of screening.
Hiyama E
Ann Acad Med Singap; 2008 Dec; 37(12 Suppl):88-4. PubMed ID: 19904462
[TBL] [Abstract][Full Text] [Related]
19. Incidence of neuroblastoma after a screening program.
Barrette S; Bernstein ML; Robison LL; Samson Y; Brossard J; Weitzman S; Woods WG
J Clin Oncol; 2007 Nov; 25(31):4929-32. PubMed ID: 17971590
[TBL] [Abstract][Full Text] [Related]
20. A population-based study of the usefulness of screening for neuroblastoma.
Woods WG; Tuchman M; Robison LL; Bernstein M; Leclerc JM; Brisson LC; Brossard J; Hill G; Shuster J; Luepker R; Byrne T; Weitzman S; Bunin G; Lemieux B
Lancet; 1996 Dec 21-28; 348(9043):1682-7. PubMed ID: 8973429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
